S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 10.96 CNY -0.81% Market Closed
Market Cap: 13.7B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Accounts Receivables
ÂĄ1.3B
CAGR 3-Years
-7%
CAGR 5-Years
4%
CAGR 10-Years
14%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accounts Receivables
ÂĄ3.2B
CAGR 3-Years
5%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accounts Receivables
ÂĄ809.6m
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
15%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accounts Receivables
ÂĄ6.2B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accounts Receivables
ÂĄ10.1B
CAGR 3-Years
15%
CAGR 5-Years
40%
CAGR 10-Years
27%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accounts Receivables
ÂĄ98.4m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
13.7B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stands as a prominent player in the global pharmaceutical landscape, carving its niche with a remarkable story of specialization and expansion. Founded in 1998, the company first made its mark as a leading producer of heparin sodium, a critical anticoagulant used worldwide to prevent and treat blood clots. Operating from Shenzhen, China, Hepalink has meticulously built an integrated production chain that spans from the procurement of raw materials to the sale of finished pharmaceutical products. The company sources raw heparin from porcine intestines, which it then processes into pharmaceutical-grade heparin and low molecular weight heparins (LMWHs), leveraging its proprietary purification and synthesis technologies. This robust vertical integration not only ensures quality control but also bolsters its competitive positioning in global markets, where it serves hospitals, pharmaceutical companies, and research institutions. Beyond its heparin-centric foundation, Hepalink has strategically expanded its portfolio through a series of calculated ventures and acquisitions aimed at broadening its business model and revenue streams. Over the years, it has diversified into contract development and manufacturing services (CDMO), biotechnology innovations, and the production of other complementary pharmaceutical products. Its acquisition strategies, such as the purchase of U.S.-based Cytovance Biologics, have been pivotal in gaining an international footprint and enriching its expertise in biologics. By investing in research and development, Hepalink continues to explore biologically derived treatments, aiming to lead in therapeutic areas like oncology and cardiology. This diversification effort not only mitigates the risks inherent in relying heavily on a single product line but also positions Hepalink as an agile and innovative player, ready to navigate the ever-evolving pharmaceutical industry landscape.

Intrinsic Value
13.81 CNY
Undervaluation 21%
Intrinsic Value
Price
S

See Also

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Accounts Receivables?
Accounts Receivables
1.3B CNY

Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Accounts Receivables amounts to 1.3B CNY.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
14%

Over the last year, the Accounts Receivables growth was 6%. The average annual Accounts Receivables growth rates for Shenzhen Hepalink Pharmaceutical Group Co Ltd have been -7% over the past three years , 4% over the past five years , and 14% over the past ten years .

Back to Top